IPM Brief – Issue 27 | The Fine Print Is Practising Medicine

Dear friends,

September has barely started, and somebody has already scheduled a meeting to discuss why the last meeting produced no decisions. To anyone still on holiday: protect your peace. The rest of us have been reunited with the reply-all button.

There is, however, something to be said for people doing things together.

Sociologists have a rather elegant term for what happens when people experience the same thing at the same time: “collective effervescence.” The feeling becomes larger because it is shared.

Health systems could use a little more of it.

Not the chanting or the wristbands. The useful part is what happens when separate actors begin moving in the same direction: when a diagnostic result actually changes treatment; when one regulator trusts another’s assessment; when reimbursement follows scientific possibility; when health data can move without becoming less secure; and when public-health institutions keep doing the unglamorous work long enough for a preventable disease to disappear.

Because medicine is not short of extraordinary possibilities.

This week, a blood test can trigger a change in cancer treatment before a scan shows progression. A rare neurological disease has its first treatment — and a formidable price. One regulator is trusting another enough to put a deadline on duplication. A hospital has discovered that an inadequate login system can become a very expensive policy failure.

These look like very different stories. They are not.

Each asks essentially the same question: what has to happen around an innovation for it to produce an actual benefit for people?

Increasingly, the difficult part is not simply discovering the science. It is deciding what counts as sufficient evidence, whose assessment travels, who pays, who gets access, who protects the data and who remains accountable when the system fails.

There is progress here, and plenty worth defending. But breakthroughs do not become health outcomes by themselves. They need rules, institutions and people capable of moving together.

This week, the fine print has put on a white coat.

We should probably ask who wrote it.

In this issue

• The Blood Test Has Overruled “Wait and See”: A breast-cancer approval turns emerging resistance into a reason to act before progression.
• A $12 Billion Deal Cannot Buy a Positive Trial: Novartis’s acquired muscle-disease programme misses its pivotal test.
• A First Treatment. A Million-Dollar Question: Alexander disease gets a breakthrough; access gets a difficult negotiation.
• Forty-Five Days. That Is What Regulatory Trust Can Buy: Mexico opens a faster medicines route based on Brazil’s assessments.
• Macron Wants to Put an Age Limit on the Algorithm: A proposed EU-wide social-media ban puts child protection on Brussels’s agenda.
• One Login. Half a Million Patients: A hospital data breach produces a fine and an uncomfortable lesson in accountability.
• The Vaccine Queue Is Getting New Rules: A global mpox stockpile aims to make outbreak response less dependent on purchasing power.
• The Dogs Got Vaccinated. The System Worked: Bhutan’s rabies milestone makes a powerful case for sustained public-health investment.

This is not another health news digest. It’s a twice-weekly readout of where evidence meets power and where power must turn into action.

---

The Blood Test Has Overruled “Wait and See”

Waiting for a cancer to visibly progress has just lost some of its authority. On 4 September, the FDA granted accelerated approval to AstraZeneca’s camizestrant, alongside a CDK4/6 inhibitor, for eligible adults with advanced HR-positive, HER2-negative breast cancer when an ESR1 mutation emerges during treatment. The approach uses a blood test to identify resistance before scan-confirmed progression. In the 315-patient SERENA-6 trial, switching the endocrine treatment produced median progression-free survival of 16 months versus 9.2 months with continued aromatase-inhibitor treatment. (FDA)

The scientific opportunity comes with a financing question: who pays to keep looking? Repeated molecular testing becomes part of the treatment pathway, with access potentially determining who benefits from the new strategy. The approval remains accelerated, overall-survival data were immature, and continued approval may depend on confirmatory evidence. Those qualifications matter. So does the implementation challenge: a health system cannot celebrate an earlier intervention while leaving the test that triggers it outside the budget.

---

A $12 Billion Deal Cannot Buy a Positive Trial

The acquisition cleared. The trial did not. On 8 September, Novartis said del-desiran failed to deliver a statistically significant improvement over placebo on the primary endpoint of its Phase III HARBOR study in myotonic dystrophy type 1. The endpoint measures how quickly patients can open their hands after clenching them. The experimental therapy entered Novartis’s pipeline through its approximately $12 billion acquisition of Avidity. The company reported activity in secondary and exploratory analyses and is reviewing the full results before determining the next development steps. (Novartis; Reuters)

This is the awkward boundary between financial confidence and clinical proof. Buying a promising programme transfers ownership of the risk; it does not remove it. Secondary signals deserve examination, but the agreed primary test cannot become optional because the acquisition was expensive. For policymakers, the challenge is to sustain investment in difficult diseases while maintaining independent evidentiary standards. For patients, the disappointment is measured in lost possibilities rather than market capitalisation.

---

A First Treatment. A Million-Dollar Question

For families living with Alexander disease, preserving the ability to walk is an outcome with an address, a school run and a staircase attached. On 3 September, the FDA approved Ionis’s zilganersen, marketed as Zanvastro, for children and adults with the rare neurological disorder. The RNA-targeted treatment reduces production of GFAP, the protein implicated in the disease. In the pivotal analysis among patients aged five and older, treatment significantly stabilised walking speed compared with control at 61 weeks. Administration is by injection into the spinal canal every three months. (Ionis; Reuters)

Then comes the access negotiation. Ionis announced a price of $285,000 per dose: approximately $1.14 million for four doses, before discounts and administration costs. That is not a prediction of what a family pays, but it is a substantial challenge for coverage decisions. The breakthrough deserves recognition. It also deserves an access model that can withstand scrutiny: transparent eligibility, workable reimbursement and continuing evidence about durability. Families should not have to become reimbursement experts to benefit from molecular expertise.

---

Forty-Five Days. That Is What Regulatory Trust Can Buy

A remarkably consequential piece of paperwork has emerged in Latin America. In an announcement published on 3 September, Anvisa said Mexico had established a simplified registration procedure using the Brazilian regulator’s assessments. The route covers several categories, including new medicines, generics, biotechnology products and vaccines. Eligible products must match the essential characteristics of the Brazilian authorisation, which must remain valid. Once the required dossier is complete, the Mexican authority has a maximum of 45 working days to decide. (Anvisa)

Cofepris retains its decision-making authority; this is reliance on an assessment, rather than automatic approval. The political significance is substantial. Regional health sovereignty can be built through institutions trusting each other enough to stop repeating work. Faster registration does not guarantee procurement, reimbursement or supply, but it can remove one avoidable delay. The test now is whether the administrative promise becomes a functioning route that manufacturers use and patients feel. Regulatory cooperation has acquired something unusually useful: a clock.

---

Macron Wants to Put an Age Limit on the Algorithm

The school gates have reopened, and Emmanuel Macron wants the digital gates narrowed. On 8 September, his office said he had urged the European Commission to pursue an EU-wide social-media ban for under-15s. The request, in a letter dated 29 August, follows the Constitutional Council’s rejection of France’s national legislation. It is a political proposal, not an enacted European ban. (Reuters)

Brussels should demand an implementation case as serious as the ambition. How would age checks protect privacy? What outcomes would establish that restrictions improve children’s wellbeing? Who would enforce the rules, and what responsibilities would remain with platforms? Child protection deserves more than an attractive age threshold. A policy that merely relocates responsibility to parents or turns identification into the price of participation would leave difficult questions unanswered. The objective should be a safer digital environment, with measurable duties for the companies operating it.

---

One Login. Half a Million Patients

The attacker did not need an account for every patient. One compromised account opened the door to the hospital’s entire patient database. In a 3 September announcement, France’s CNIL disclosed a €500,000 fine against Hôpital Privé de la Loire after a breach in summer 2025 exposed data concerning 524,867 patients and 202,246 trusted contacts. The regulator identified weak external authentication, excessive access permissions and inadequate detection of suspicious activity. It also found that the trusted contacts had not been directly informed. (CNIL)

For every minister promoting a seamless digital health system, here is the less glamorous procurement question: seamless for whom? Clinical access must follow responsibility for care, and abnormal behaviour must be detectable before a database has been explored for days. The hospital strengthened security during the proceedings, with further measures required. That matters, but the broader lesson concerns governance. A strategy to collect more health data needs equally concrete decisions about who may reach it, who notices misuse and who answers when protection fails.

---

The Vaccine Queue Is Getting New Rules

A stockpile is an unglamorous object with considerable geopolitical potential. In a 2 September announcement, WHO and partners detailed a global mpox vaccine stockpile initiative launched on 27 August and scheduled to begin operating later in September. Funded by Gavi and coordinated through the International Coordinating Group on Vaccine Provision, it is designed to serve countries worldwide. WHO reported that two-thirds of reported mpox cases were occurring in the African Region, underlining why the geography of vaccination cannot simply follow purchasing power. (WHO)

The achievement is an allocation mechanism with financing behind it. That is more useful than another declaration that vaccines should be shared. But a global reserve becomes protection only when requests are processed, doses travel and local services can administer them. The measures of success should therefore be operational: time to delivery, coverage of people at risk and support for deployment. Equity needs a shipping date. This initiative creates a route towards one; the coming months must show that it works.

---

The Dogs Got Vaccinated. The System Worked

Sometimes the strongest health story ends with fewer emergencies and very little theatre. On 4 September, WHO validated Bhutan’s elimination of dog-transmitted human rabies as a public-health problem, the first such achievement in its South-East Asia Region. The country has recorded no human deaths from dog-mediated rabies since June 2023. Behind that result sit years of dog vaccination, access to treatment after exposure, coordinated surveillance and cooperation between human-health services, veterinary teams and communities. (WHO)

This is a political success precisely because it required institutions to keep doing the work after the launch photographs were taken. Bhutan will maintain free post-exposure prophylaxis across all 20 districts, alongside vaccination and surveillance; elimination is an achievement to sustain, not permission to dismantle the programme. For governments hunting the next prestigious health announcement, there is a useful provocation here. Competence can be transformative. A functioning public service, financed consistently and organised around a preventable death, can deliver a result that no slogan can manufacture.

---

The IPM Take

The question is not how much regulation medicine can tolerate. It is whether the rules are doing useful work for patients. A rule can authorise earlier treatment, preserve an honest clinical test, accelerate a trusted assessment or protect a medical record. It can also leave an access problem unresolved.

The political test is what happens after the announcement: who receives care, who remains exposed and who is accountable. The fine print should have to answer in patient outcomes.

---

September Watch

Registrations also remain open for upcoming IPM Alliance events in New York on 24 September and Dublin on 2 October. Visit the IPM Alliance website for programme updates.

---

Follow the last-mile conversation!

IPM Alliance tracks the decisions, bottlenecks and implementation gaps shaping personalised medicine access. Follow us for briefings, events, policy signals and practical insights from across regions and disease areas.

• LinkedIn
• YouTube
• X

---

We want to hear from you

When a patient becomes eligible for personalised care, where does the system most often lose them: identification, testing, referral, reimbursement, delivery capacity or equity?

---

Know someone who should be reading this?

IPM Brief is built for people working where science, policy and patient access collide. If one colleague would find this useful, forward it to them and help bring them into the conversation.

---

International Alliance for Personalised Medicine

Avenue de l’Armée / Legerlaan 10, 1041 Brussels, Belgium